pertscan-99m
Small moleculeexperimentalImaging agent
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 15, 2017 (NCT03120624)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Mol. weight
- 185.89 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- Yes
- Polymer
- No
- Delivery
- Oral, Parenteral, Topical
- Availability
- Prescription Only
- Imaging
- 99-technetium
Oral
Yes
Parenteral
Yes
Topical
Yes
Sources
- ChEMBLCHEMBL2096641 ↗
Also known as
- pertscan-99m
- pertscan-99m
- tc 99m generator
- tc 99m generator
- tc-99m sodium pertechnetate
- technetium tc-99m sodium pertechnetate
- ultra-technekow fm
- ultra-technekow fm
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03120624 | Phase 1 | Jun 15, 2017 | Mayo Clinic, National Cancer Institute (NCI) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2017 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2017 |
2 organizations
Page 1 / 1